Genome-Wide Association Studies Market Report 2026

Genome-Wide Association Studies Market Overview

• Genome-Wide Association Studies market size has reached to $2.27 billion in 2025 • Expected to grow to $4.26 billion in 2030 at a compound annual growth rate (CAGR) of 13.4% • Growth Driver: Increasing Demand For Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomics And Targeted Treatment Strategies • Market Trend: Innovative Research Platforms Accelerate Disease Discovery • North America was the largest region in 2025.

What Is Covered Under Genome-Wide Association Studies Market?

Genome-wide association studies (GWAS) refer to research studies that scan the entire genome of many individuals to identify genetic variations associated with specific diseases or traits. It helps to uncover genetic factors that contribute to complex diseases or traits, helping in risk prediction, understanding disease mechanisms, and guiding the development of targeted therapies. The main product types of genome-wide association studies are genotyping services, genotyping kits and reagents, software and data analysis tools, and others. Genotyping services are laboratory services that analyze DNA to identify genetic variations for research, diagnostics, and personalized medicine. These are applied in drug discovery, disease risk assessment, personalized medicine, and others, serving end-users including pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinics, and others.

What Is The Genome-Wide Association Studies Market Growth Forecast?

The genome-wide association studies market size is expected to see rapid growth in the next few years. It will grow to $4.26 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing demand for precision medicine insights, rising investments in genomic analytics platforms, expansion of ai-driven genetic research, growing pharmaceutical interest in target discovery, increasing focus on predictive healthcare models. Major trends in the forecast period include increasing adoption of large-scale population genomics studies, rising use of advanced bioinformatics platforms, growing integration of gwas in drug discovery, expansion of personalized medicine research programs, enhanced focus on disease risk prediction.

Global Genome-Wide Association Studies Market Segmentation

1) By Product Type: Genotyping Services, Genotyping Kits And Reagents, Software And Data Analysis Tools, Other Product Types 2) By Application: Drug Discovery, Disease Risk Assessment, Personalized Medicine, Other Applications 3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Clinics, Other End-Users Subsegments: 1) By Genotyping Services: Whole Genome Sequencing (Wgs), Exome Sequencing, Targeted Genotyping 2) By Genotyping Kits And Reagents: Dna Extraction Kits, Sequencing Reagents, Library Preparation Kits 3) By Software And Data Analysis Tools: Bioinformatics Platforms, Data Visualization Tools, Statistical Analysis Software 4) By Other Product Types: Sample Collection Devices, Quality Control Tools, Laboratory Consumables

What Is The Driver Of The Genome-Wide Association Studies Market?

The increasing demand for personalized medicine is expected to propel the growth of the genome-wide association studies market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The increasing adoption of personalized medicine is primarily due to advancements in genomics, which enable precise identification of genetic variations and tailored treatments for individuals. Genome-wide association studies (GWAS) enhance personalized medicine by identifying genetic variations linked to diseases, enabling targeted treatment strategies. They improve healthcare outcomes by providing insights into individual risk profiles and supporting precision therapies. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the genome-wide association studies industry.

Key Players In The Global Genome-Wide Association Studies Market

Major companies operating in the genome-wide association studies market are F. Hoffmann-La Roche AG, AstraZeneca plc, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Eurofins Scientific SE, Laboratory Corporation of America Holdings, Daiichi Sankyo Company Limited, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Databricks Inc., Broad Institute of MIT and Harvard, BGI Genomics Co. Ltd., deCODE genetics Inc., Genomics England Ltd., CD Genomics Inc., Veritas Genetics Inc., Finngen, The Wellcome Sanger Institute

Global Genome-Wide Association Studies Market Trends and Insights

Major companies operating in the genome-wide association studies market are focusing on developing innovative solutions, such as advanced research platforms to accelerate disease discovery and personalized medicine applications. An advanced research platform is an integrated system of tools and technologies that enables large-scale genomic data generation, analysis, and interpretation for genome-wide association studies. For instance, in January 2025, 23andMe Holding Co., a US-based biotechnology company, launched Discover23, a consumer-facing platform for genetic insights and ancestry exploration. It enables biopharma collaborators to access comprehensive genetic data through a trusted environment powered by Lifebit. It provides analysis-ready genome-wide association studies (GWAS) on over 1,000 disease cohorts, derived from billions of phenotypic data points from millions of consenting participants. The advanced research platform aims to accelerate drug discovery by helping researchers identify novel disease biology and potential drug targets and improve clinical trial success while maintaining participant privacy.

What Are Latest Mergers And Acquisitions In The Genome-Wide Association Studies Market?

In May 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired 23andMe Holding Co. for $256 million. With this acquisition, Regeneron Pharmaceuticals aims to leverage one of the largest consumer genetic databases to accelerate genomics-driven drug discovery, improve precision medicine, and advance health through large-scale genetic research while maintaining strong data privacy and ethical standards. 23andMe Holding Co. is a US-based biotechnology company that offers genome-wide association studies.

Regional Outlook

North America was the largest region in the genome-wide association studies market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Genome-Wide Association Studies Market?

The genome-wide association studies market includes revenues earned by entities through sequencing, data analysis, bioinformatics support, biomarker discovery, and consulting for genetic association studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Genome-Wide Association Studies Market Report 2026?

The genome-wide association studies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the genome-wide association studies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.